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A bs tr ac t
Background
Approximately 50% of patients with heart failure have a left ventricular ejection 
fraction of at least 45%, but no therapies have been shown to improve the outcome 
of these patients. Therefore, we studied the effects of irbesartan in patients with 
this syndrome.
Methods
We enrolled 4128 patients who were at least 60 years of age and had New York Heart 
Association class II, III, or IV heart failure and an ejection fraction of at least 45% 
and randomly assigned them to receive 300 mg of irbesartan or placebo per day. 
The primary composite outcome was death from any cause or hospitalization for a 
cardiovascular cause (heart failure, myocardial infarction, unstable angina, ar-
rhythmia, or stroke). Secondary outcomes included death from heart failure or 
hospitalization for heart failure, death from any cause and from cardiovascular 
causes, and quality of life.
Results
During a mean follow-up of 49.5 months, the primary outcome occurred in 742 
patients in the irbesartan group and 763 in the placebo group. Primary event rates 
in the irbesartan and placebo groups were 100.4 and 105.4 per 1000 patient-years, 
respectively (hazard ratio, 0.95; 95% confidence interval [CI], 0.86 to 1.05; P = 0.35). 
Overall rates of death were 52.6 and 52.3 per 1000 patient-years, respectively (haz-
ard ratio, 1.00; 95% CI, 0.88 to 1.14; P = 0.98). Rates of hospitalization for cardio-
vascular causes that contributed to the primary outcome were 70.6 and 74.3 per 
1000 patient-years, respectively (hazard ratio, 0.95; 95% CI, 0.85 to 1.08; P = 0.44). 
There were no significant differences in the other prespecified outcomes.
Conclusions
Irbesartan did not improve the outcomes of patients with heart failure and a pre-
served left ventricular ejection fraction. (ClinicalTrials.gov number, NCT00095238.)
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A pproximately half of patients with a diagnosis of heart failure have a normal or near-normal left ventricular ejection 
fraction.1-5 Such patients differ from those with 
heart failure and a low left ventricular ejection 
fraction in a number of important ways: they 
tend to be older and female, and their condition 
is more likely to be associated with hypertension 
than with ischemia. The rates of death and ill-
ness among these patients are high and have not 
declined, as they have in patients with heart fail-
ure and a low left ventricular ejection fraction.6
Unfortunately, no pharmacologic therapy has 
been shown to be effective in improving outcomes 
in patients with heart failure with a preserved left 
ventricular ejection fraction. However, because the 
renin–angiotensin–aldosterone system is involved 
in many of the processes associated with this syn-
drome (including hypertension, left ventricular 
hypertrophy, myocardial fibrosis, and vascular 
dysfunction),7,8 inhibitors of this system have been 
of particular interest as a ther apeutic intervention 
for these patients.9,10 Although information about 
neurohormone levels in this syndrome is limited, 
available data indicate that plasma renin activity 
is increased in patients with heart failure and a 
preserved left ventricular ejection fraction, as com-
pared with control subjects, although levels are 
lower than in patients who have heart failure with 
a low left ventricular ejection fraction.7 Further-
more, blockade of the renin–angiotensin system 
has had favorable effects in patients with a low left 
ventricular ejection fraction. It has also improved 
outcomes in patients after myocardial infarction, 
in those with hypertension, and in those with 
other high-risk vascular disease — populations 
that are thought to be at risk for heart failure with 
a preserved left ventricular ejection fraction.
Accordingly, we conducted the Irbesartan in 
Heart Failure with Preserved Ejection Fraction 
Study (I-PRESERVE) to evaluate the effect of the 
angiotensin-receptor blocker irbesartan on mor-
tality and cardiovascular morbidity in patients with 
heart failure and a preserved left ventricular ejec-
tion fraction.
Me thods
Patients
We enrolled patients from centers in 25 countries. 
All patients were at least 60 years of age and 
had heart failure symptoms and a left ventricular 
ejection fraction of at least 45%.11,12 In addition, 
we required patients to have been hospitalized 
for heart failure during the previous 6 months 
and have current New York Heart Association 
(NYHA) class II, III, or IV symptoms with corrobo-
rative evidence; if they had not been hospitalized, 
they were required to have ongoing class III or IV 
symptoms with corroborative evidence. Such evi-
dence could include findings of pulmonary con-
gestion on radiography, left ventricular hypertro-
phy or left atrial enlargement on echocardiography, 
or left ventricular hypertrophy or left bundle-
branch block on electrocardiography. Treatment 
with an angiotensin-converting–enzyme (ACE) 
inhibitor was permitted only when such therapy 
was considered essential for an indication other 
than uncomplicated hypertension.
Exclusion criteria included previous intolerance 
to an angiotensin-receptor blocker; an alternative 
probable cause of the patient’s symptoms (e.g., 
significant pulmonary disease); any previous left 
ventricular ejection fraction below 40%; a history 
of acute coronary syndrome, coronary revascular-
ization, or stroke within the previous 3 months; 
substantial valvular abnormalities; hypertrophic 
or restrictive cardiomyopathy; pericardial disease; 
cor pulmonale or other cause of isolated right 
heart failure; a systolic blood pressure of less 
than 100 mm Hg or more than 160 mm Hg or a 
diastolic blood pressure of more than 95 mm Hg 
despite antihypertensive therapy; other system-
ic disease limiting life expectancy to less than 
3 years; substantial laboratory abnormalities (such 
as a hemoglobin level of less than 11 g per deci-
liter, a creatinine level of more than 2.5 mg per 
deciliter [221 μmol per liter], or liver-function ab-
normalities); or characteristics that might inter-
fere with compliance with the study protocol.
Study Procedures
The trial was approved by the ethics committee 
at each participating center; all patients provided 
written informed consent. Eligible patients were 
treated with single-blind placebo for 1 to 2 weeks 
before randomization; those who successfully com-
pleted this run-in phase and whose condition re-
mained clinically stable were randomly assigned in 
a 1:1 ratio to receive irbesartan or matching place-
bo. The randomization schedule was implement-
ed with the use of an interactive voice-response 
system. The randomization block size was two 
and was stratified according to site. Patients were 
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also stratified according to their use of an ACE 
inhibitor at randomization. Therefore, for each 
site, separate blocks of two were designated for 
patients who were taking an ACE inhibitor and 
for those who were not taking an ACE inhibitor. 
Randomization of patients who were taking an 
ACE inhibitor at baseline was capped at 33% at 
each site.
Patients were started on 75 mg of irbesartan 
or placebo once daily. The dose was doubled to 
150 mg after 1 to 2 weeks and was doubled again 
to 300 mg after an additional 1 to 2 weeks, accord-
ing to a forced-titration protocol as tolerated. In 
addition to the titration visits, patients were seen 
8 weeks, 14 weeks, and 6 months after random-
ization and every 4 months thereafter. The score 
on the Minnesota Living with Heart Failure 
scale13 and the plasma level of N-terminal pro-
B–type natriuretic peptide (NT-proBNP) were re-
corded at randomization, at 6 and 14 months, 
and at the final study visit. Serum creatinine and 
potassium were measured before randomization 
and at weeks 2 and 8, at month 6, and annually 
thereafter and, along with NT-proBNP, were ana-
lyzed in a central laboratory (Esoterix Belgium).
The executive committee designed and over-
saw the trial in collaboration with representatives 
of the study sponsors (Bristol-Myers Squibb and 
Sanofi-Aventis), with assistance from an interna-
tional steering committee. The sponsors or a 
contract research organization collected the trial 
data, which were then analyzed at the Statistical 
Data Analysis Center at the University of Wis-
consin, Madison, independently of the sponsors 
and according to a predefined statistical analysis 
plan. All investigators and committee members 
who were involved in the conduct of the study 
(except for members of the data and safety moni-
toring board) were unaware of study-group as-
signments. The manuscript was prepared and 
submitted for publication by members of the 
executive committee, who had unrestricted access 
to the study data and who vouch for the accu-
racy and completeness of the reported analyses.
Study Outcomes and Definitions
The primary outcome, which was analyzed as the 
time from randomization to the first event, was a 
composite of death from any cause or hospital-
ization for a protocol-specified cardiovascular 
cause. Reasons for such hospitalizations includ-
ed worsening heart failure, myocardial infarc-
tion, stroke, unstable angina, ventricular or atrial 
dysrhythmia, or myocardial infarction or stroke 
that occurred during any hospitalization. The sec-
ondary outcomes were the components of the 
primary outcome (death from any cause and hos-
pitalization for cardiovascular causes), a compos-
ite heart failure outcome (death due to worsening 
heart failure or sudden death or hospitalization 
due to worsening heart failure), a change in the 
total score on the Minnesota Living with Heart 
Failure scale at 6 months, a change in the plasma 
level of NT-proBNP at 6 months, a composite 
vascular-event outcome (death from cardiovas-
cular causes, nonfatal myocardial infarction, or 
nonfatal stroke), and death from cardiovascular 
causes. Deaths and hospitalizations were adjudi-
cated by members of an independent end-point 
committee who were unaware of study-group as-
signments and used prespecified criteria.
Statistical Analysis
We originally anticipated an annual event rate of 
18% for the primary outcome in the placebo 
group. A sample size of 3600 patients was planned 
to provide 1440 primary events, yielding a statis-
tical power of 90% to detect a 14.5% reduction in 
risk with irbesartan, corresponding to a reduction 
in hazard of 15.75%, with a two-sided alpha of 
0.05, assuming a recruitment period of 2 years 
and a minimum follow-up period of 2 years. A 
blinded review of event rates in 2004 indicated 
that outcomes had accumulated at a slower-than-
anticipated rate. Consequently, to achieve the tar-
get number of events for the same decrease in the 
hazard in a reasonable time period, the sample 
size was increased to 4100 patients.
Data from all patients who underwent ran-
domization were analyzed according to the inten-
tion-to-treat principle. The analyses of the pri-
mary outcome and other composites of death or 
hospitalization were performed with the use of 
Kaplan–Meier estimates, with the log-rank test 
for the comparison of the study groups, and a 
supportive Cox proportional-hazards model to 
calculate hazard ratios and 95% confidence in-
tervals. Consistency of effects was assessed for 
eight prespecified subgroups, according to age 
(<65, 65 to 75, and >75 years), sex, ejection frac-
tion (≤59% or >59%), the use or nonuse of ACE 
inhibitors and beta-blockers, the presence or ab-
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sence of diabetes, hospitalization for heart fail-
ure within the previous 6 months, and geograph-
ic region (Europe, North America, or all other 
countries). Interactions were evaluated by fitting 
an interaction term between treatment and each 
of the eight covariates and then assessing signifi-
cance with the use of a Wald test. The score on 
the Minnesota Living with Heart Failure scale and 
the log-transformed plasma level of NT-proBNP 
were studied by analysis of covariance, with the 
baseline value as a covariate. All analyses included 
the use of ACE inhibitors as a term in the model. 
To control for the global type I error, the study 
outcomes were examined in a prespecified se-
quence as described previously. If at any step su-
periority was not demonstrated at the 0.05 level, 
no conclusion would be drawn for subsequent 
outcomes. All P values are two-sided and were 
not adjusted for multiple testing.
The protocol specified that the data and safety 
monitoring board should conduct a single interim 
efficacy analysis for mortality from any cause 
after 50% of the total expected deaths had oc-
curred. For this analysis, the Pocock approach was 
applied for harm and the O’Brien–Fleming ap-
proach was applied for benefit.
R esult s
Patients
From June 2002 through April 2005, a total of 4563 
patients were formally screened and 4128 under-
went randomization at 293 sites in 25 countries in 
Western Europe, Eastern Europe, North America, 
South America, South Africa, and Australia. Of 
those patients, 2067 were assigned to receive irbe-
sartan and 2061 to receive placebo. The common 
study termination date was set for April 17, 2008, 
when it was estimated that at least 1440 events of 
the primary outcome would have occurred. The 
mean follow-up time was 49.5 months, and the 
trial included 16,798 patient-years of follow-up.
The study groups did not differ significantly in 
baseline characteristics (Table 1). The mean age 
was 72 years, and 60% of the patients were wom-
en. The primary cause of heart failure was hyper-
tension in 64% of the patients and ischemic heart 
disease in 25%, and hypertension was present in 
88% overall. Atrial fibrillation was present in 29% 
and diabetes mellitus in 27%. Forty-one percent 
of the patients were obese, which was defined 
as a body-mass index (the weight in kilograms 
divided by the square of the height in meters) of 
more than 30. At baseline, the median level of 
NT-ProBNP was 339 pg per milliliter (interquartile 
range, 133 to 964). Baseline medications included 
diuretics (83%, including 52% who were taking a 
loop diuretic), beta-blockers (59%), calcium-chan-
nel blockers (40%), spironolactone (15%), and ACE 
inhibitors (25%).
Study-Drug Administration and Follow-up
At the end of the titration phase, 84% of the pa-
tients in the irbesartan group and 88% of those 
in the placebo group had reached the 300-mg 
dose (mean doses, 275 mg and 284 mg, respective-
ly). The proportion of patients reaching the tar-
get dose did not differ according to the use of an 
ACE inhibitor. During the study, the proportion 
of patients receiving an ACE inhibitor rose from 
25% in the two groups at baseline to 39% in the 
irbesartan group and 40% in the placebo group, 
the use of spironolactone rose from 15% in the 
two groups at baseline to 28% in the irbesartan 
group and 29% in the placebo group, and the use 
of beta-blockers rose from 59% in the irbesartan 
group and 58% in the placebo group to 73% in the 
two groups.
Between baseline and 6 months, blood pres-
sure declined by a mean (±SD) of 3.8±18.0 mm Hg 
systolic and 2.1±10.5 mm Hg diastolic in the irbe-
sartan group and by a mean of 0.2±17.6 mm Hg 
systolic and 0.2±10.4 mm Hg diastolic in the 
placebo group; the decreases in the two groups 
persisted for the duration of the trial. Among the 
surviving patients, the discontinuation rates in 
the irbesartan group and in the placebo group, 
respectively, were 13% and 12% at 1 year, 21% 
and 20% at 2 years, and 34% and 33% at the end 
of the trial.
At the end of the study, vital-status data were 
not available for 29 patients (1%) in the irbesartan 
group and 44 patients (2%) in the placebo group. 
If contact could not be made at end of study, data 
for these patients were censored from the analysis 
at the date they were last known to be alive.
Primary Outcome
The primary composite outcome occurred in 742 
patients (36%) in the irbesartan group and in 763 
patients (37%) in the placebo group. There were 
100.4 end-point events per 1000 patient-years in 
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Table 1. Baseline Characteristics of the Patients.*
Characteristic Placebo (N = 2061) Irbesartan (N = 2067)
Demographic
Age
Mean — yr 72±7 72±7
≥75 yr — no. (%) 716 (35) 697 (34)
Female sex — no. (%) 1264 (61) 1227 (59)
Race — no. (%)†
White 1925 (93) 1934 (94)
Black 43 (2) 39 (2)
Asian 15 (1) 19 (1)
Other 78 (4) 75 (4)
Clinical
NYHA class — no. (%)‡
II 445 (22) 426 (21)
III 1562 (76) 1582 (77)
IV 53 (3) 59 (3)
Heart rate — beats/min 71±10 72±11
Blood pressure — mm Hg
Systolic 136±15 137±15
Diastolic 79±9 79±9
Body-mass index 29.6±5.3 29.7±5.3
Electrocardiographic findings — no. (%)
Left ventricular hypertrophy 624 (30) 636 (31)
Left bundle-branch block 169 (8) 167 (8)
Atrial fibrillation or flutter 344 (17) 353 (17)
Ejection fraction 0.60±0.09 0.59±0.09
Cause of heart failure — no. (%)
Ischemia 500 (24) 536 (26)
Hypertension 1304 (63) 1318 (64)
Hospitalization for heart failure within previous 6 mo — no. (%) 906 (44) 910 (44)
Medical history — no. (%)
Hypertension 1816 (88) 1834 (89)
Angina symptoms§ 824 (40) 828 (40)
Unstable angina 149 (7) 166 (8)
Myocardial infarction 482 (23) 487 (24)
PCI or CABG 267 (13) 281 (14)
Atrial fibrillation 603 (29) 606 (29)
Diabetes mellitus 564 (27) 570 (28)
Stroke or transient ischemic attack 201 (10) 198 (10)
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Table 1. (Continued.)
Characteristic Placebo (N = 2061) Irbesartan (N = 2067)
Quality of life
Score on the Minnesota Living with Heart Failure scale¶ 
Median 42 42
Interquartile range 28–58 27–58
Laboratory measurements
Hemoglobin
Mean — g/dl 14±2 14±2
Anemia — no. (%)‖ 258 (13) 256 (12)
Creatinine — mg/dl 1.0±0.34 1.0±0.32
Estimated glomerular filtration rate
Mean — ml/min/1.73 m2 of body-surface area 72±22 73±23
<60 ml/min/1.73 m2 — no. (%) 613 (30) 632 (31)
Potassium — mmol/liter 4.5±0.5 4.4±0.5
NT-proBNP — pg/ml**
Median 320 360
Interquartile range 131–946 139–987
Medication — no. (%)
Diuretic†† 1721 (84) 1696 (82)
Loop 1072 (52) 1078 (52)
Thiazide 779 (38) 776 (38)
Spironolactone 313 (15) 320 (15)
ACE inhibitor 510 (25) 538 (26)
Digoxin 269 (13) 291 (14)
Beta-blocker 1202 (58) 1225 (59)
Antiarrhythmic drug 175 (8) 184 (9)
Calcium-channel blocker 811 (39) 825 (40)
Nitrate 550 (27) 558 (27)
Oral anticoagulant 398 (19) 392 (19)
Antiplatelet 1193 (58) 1222 (59)
Lipid-lowering agent 623 (30) 656 (32)
* Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. The body-mass index is the 
weight in kilograms divided by the square of the height in meters. To convert the values for creatinine to micromoles 
per liter, multiply by 88.4. ACE denotes angiotensin-converting enzyme, CABG coronary-artery bypass grafting, NT-
proBNP N-terminal pro-B–type natriuretic peptide, NYHA New York Heart Association, and PCI percutaneous coro-
nary intervention.
† Race was reported by the investigators.
‡ One patient in NYHA class I was mistakenly included in the placebo group.
§ This category includes any angina-like symptoms at any time in the past, with no confirmation of diagnosis of coro-
nary heart disease required.
¶ Possible scores range from 0 to 105, with lower scores indicating a better quality of life.
‖ Anemia was defined by World Health Organization criteria as a hemoglobin level of less than 13 g per deciliter in 
men and less than 12 g per deciliter in women.
** NT-proBNP levels are influenced by a variety of factors, including age, sex, body-mass index, and renal function. No 
clinically useful normal range has been established.
†† Some patients were taking both loop and thiazide diuretics.
Copyright © 2008 Massachusetts Medical Society. All rights reserved. 
Downloaded from www.nejm.org at UNIVERSITY OF DEBRECEN on April 10, 2009 . 
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 359;23 www.nejm.org december 4, 20082462
the irbesartan group and 105.4 events per 1000 
patient-years in the placebo group. The hazard 
ratio for the primary outcome in the irbesartan 
group, as compared with the placebo group, was 
0.95 (95% confidence interval [CI], 0.86 to 1.05; 
P = 0.35) (Fig. 1 and Table 2). The neutral effect of 
treatment was consistent across all prespecified 
subgroups (Fig. 2).
Secondary Outcomes
Rates of death from any cause were 52.6 and 52.3 
per 1000 patient-years in the irbesartan group 
and the placebo group, respectively (hazard ratio, 
1.00; 95% CI, 0.88 to 1.14; P = 0.98) (Table 3). The 
rates for protocol-specified hospitalization were 
70.6 and 74.3, respectively (hazard ratio, 0.95; 95% 
CI, 0.85 to 1.08; P = 0.44). There were also no sig-
nificant differences between the study groups for 
any of the other prespecified secondary outcomes 
or for hospital admissions for specific cardiovas-
cular indications or for any cause (Table 3). After 
6 months, scores on the Minnesota Living with 
Heart Failure scale improved in both groups, but 
the difference in the magnitude of change be-
tween the two groups was not significant. There 
was also no significant difference between the 
groups in the change in the level of NT-proBNP 
after 6 months.
Adverse Events
During the course of the study, 16% of patients in 
the irbesartan group and 14% of patients in the 
placebo group discontinued a study drug because 
of an adverse event (P = 0.07) (Table 4). At baseline, 
the mean levels of serum creatinine were 1.00±0.34 
mg per deciliter (88.4±30.1 μmol per liter) in the 
irbesartan group and 1.00±0.32 mg per deciliter 
(88.4±28.3 μmol per liter) in the placebo group. 
At the final visit, the mean levels of serum crea-
tinine were 1.02±0.46 mg per deciliter (90.2±40.7 
μmol per liter) in the irbesartan group and 
0.98±0.34 mg per deciliter (86.6±30.1 μmol per 
liter) in the placebo group (P = 0.11). During the 
course of the study, a doubling of the serum crea-
tinine level occurred in at least one measurement 
in 6% of patients in the irbesartan group and in 4% 
of patients in the placebo group (P < 0.001). A se-
rum potassium level of more than 6.0 mmol per 
liter occurred at least once in 3% of patients in the 
irbesartan group and in 2% of patients in the pla-
cebo group (P = 0.01). However, the differences in 
the rates of serious adverse events due to hypoten-
sion, renal dysfunction, and hyperkalemia between 
the two groups were not significant (Table 4).
Discussion
Treatment with irbesartan did not reduce the risk 
of death or hospitalization for cardiovascular 
causes among patients who had heart failure 
with a preserved left ventricular ejection fraction, 
nor did it improve any of the secondary clinical 
outcomes, including disease-specific quality of 
life. These findings are in contrast to the benefits 
seen with inhibitors of the renin–angiotensin–
aldosterone system, including angiotensin-recep-
tor blockers, in patients with heart failure with 
a low left ventricular ejection fraction.14-17 How-
ever, these findings are concordant with the re-
sults of two other studies involving patients who 
had heart failure with a preserved left ventricular 
ejection fraction, the Candesartan in Heart Failure: 
Assessment of Reduction in Mortality and Mor-
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Figure 1. Kaplan–Meier Curves for the Primary Outcome.
The primary outcome of death from any cause or hospitalization for pre-
specified cardiovascular causes (worsening heart failure, myocardial infarc-
tion, stroke, atrial or ventricular arrhythmia, and myocardial infarction or 
stroke occurring during hospitalization for any cause) is shown for patients 
receiving irbesartan and those receiving placebo. The Kaplan–Meier curves 
illustrate the time to the first event (hazard ratio in the irbesartan group, 
0.95; 95% confidence interval [CI], 0.86 to 1.05; P=0.35 by the log-rank test). 
The vertical lines represent 95% confidence intervals.
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bidity (CHARM)–Preserved trial (ClinicalTrials.
gov number, NCT00634712)17,18 and the Perindo-
pril in Elderly People with Chronic Heart Failure 
(PEP-CHF) trial.19
The reasons for the lack of benefit are uncer-
tain, but several explanations warrant consider-
ation. One possibility is that many of the patients 
may not have had heart failure, since the diag-
nosis of heart failure with a preserved left ven-
tricular ejection fraction is often not straightfor-
ward and can be mimicked by other conditions.20 
We believe that this is unlikely, since 44% of the 
patients had been hospitalized for heart failure 
within 6 months, and the remainder had at least 
NYHA class III symptoms and evidence of struc-
tural heart disease. The baseline NT-proBNP val-
ues in our trial were generally consistent with 
values used to diagnose heart failure with a pre-
served left ventricular ejection fraction in the 
outpatient setting.21-24 However, the most com-
pelling evidence that we enrolled a population 
with heart failure is the high rate at which pa-
tients had subsequent hospitalizations for heart 
failure. These hospitalizations occurred at rates 
approximately 4 to 8 times the rates observed in 
trials involving patients with hypertension and 
diabetes and those at high vascular risk.25-28
A second consideration is whether the 300-mg 
target dose of irbesartan, although the highest 
approved dose, was suboptimal for efficacy in 
this disease. However, this dose reduced sys-
tolic and diastolic blood pressure by a mean of 
3.8/2.1 mm Hg. Furthermore, the same dose of 
irbesartan reduced the onset of heart failure by 
28% in the Irbesartan in Diabetic Nephropathy 
Trial.29 On the basis of our study, we cannot as-
sess whether a higher dose would have been 
beneficial.
Several other factors may have adversely af-
fected the power of the trial. One factor was the 
high rate of study-drug discontinuation, which 
reached 34% by the end of the study, a propor-
tion that was similar to that of other heart-fail-
ure trials of this duration. A second factor was 
the high rate of concomitant use of ACE inhibi-
tors, which were taken at some time during the 
trial by 39% of patients in the irbesartan group 
and 40% of those in the placebo group, and 
spironolactone, which was taken by 28% of pa-
tients in the irbesartan group and 29% of those 
in the placebo group. In addition, 73% of patients 
in the two groups received a beta-blocker during 
the study. The treatment of a large proportion of 
patients with multiple inhibitors of the renin–
angiotensin–aldosterone system might have left 
little room for further benefit from the addition 
of an angiotensin-receptor blocker.
The patients in our study closely resembled 
those with this syndrome in the community, and 
as expected their characteristics differed from 
Table 2. Primary Outcome with Component Events.* 
Outcome Placebo  (N = 2061) Irbesartan  (N = 2067)
Hazard Ratio 
(95% CI) P Value
No. of Patients 
with Event 
Event Rate per 
1000 Patient-Yr
No. of Patients  
with Event
Event Rate per 
1000 Patient-Yr
Primary outcome 763 105.4 742 100.4 0.95 (0.86–1.05) 0.35
Death 226 221
Hospitalization for protocol-specified 
cardiovascular cause
537 521
Worsening heart failure 314 291
Myocardial infarction 54 60
Unstable angina 19 20
Stroke 79 68
Atrial arrhythmia 68 77
Ventricular arrhythmia 3 5
* Event rates were normalized for the duration of follow-up before the event occurrence.
Copyright © 2008 Massachusetts Medical Society. All rights reserved. 
Downloaded from www.nejm.org at UNIVERSITY OF DEBRECEN on April 10, 2009 . 
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 359;23 www.nejm.org december 4, 20082464
those of patients who had heart failure with a 
low left ventricular ejection fraction.12 In patients 
with a preserved ejection fraction, the pathophys-
iologic substrate of a dilated remodeled heart 
and clinically manifested atherosclerotic disease 
are either less evident or absent. Furthermore, in 
spite of the preponderance of patients with a his-
tory of hypertension, only a minority of patients 
had electrocardiographic evidence of left ven-
tricular hypertrophy. Thus, important targets for 
renin–angiotensin blockade may have been ab-
sent in this population. Two previous large trials, 
PEP-CHF and CHARM-Preserved,18,19 have also 
evaluated inhibitors of the renin–angiotensin 
system in patients with heart failure and a pre-
served left ventricular ejection fraction (predomi-
nantly in patients with a left ventricular ejection 
fraction of 50% or more), and neither showed an 
overall beneficial effect of such drugs.
In these patients, heart failure may be related 
to a variety of factors, including impairment of 
left ventricular diastolic dysfunction from myo-
cardial hypertrophy and fibrosis or altered myo-
cyte calcium handling,30-32 abnormal ventricular–
vascular coupling related to decreased vascular 
compliance,33 impaired renal handling of salt 
and fluid, and other as-yet-poorly-characterized 
abnormalities. Although data from experimental 
models suggest that inhibitors of the renin–angio-
tensin–aldosterone system may affect these ab-
normalities,34 it is unclear which of these poten-
tial mechanisms are primarily responsible for the 
clinical syndrome of heart failure with a pre-
served left ventricular ejection fraction. Although 
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Figure 2. Primary Outcome According to Prespecified Subgroups.
The plot shows hazard ratios and 95% confidence intervals for the primary outcome, with patients stratified according to eight sub-
groups prespecified in the statistical analysis plan. No heterogeneity was observed for these subgroups.
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ACE inhibitors and angiotensin-receptor blockers 
have not proved to be beneficial in heart failure 
with a preserved left ventricular ejection fraction, 
aldosterone antagonists may have more success, 
since aldosterone plays a major role in stimulat-
ing myocardial collagen formation and in inhib-
iting the turnover of extracellular matrix.35,36 
This possibility is being tested in the ongoing 
Treatment of Preserved Cardiac Function Heart 
Failure with an Aldosterone Antagonist (TOPCAT) 
trial (NCT00094302) being conducted by the Na-
tional Heart, Lung, and Blood Institute.
In conclusion, we evaluated the effect of irbe-
sartan versus placebo in patients who had heart 
failure with a preserved ejection fraction. No sig-
nificant benefit of irbesartan was shown for a 
variety of cardiovascular outcomes, including death 
Table 3. Secondary Outcomes.*
Outcome Placebo (N = 2061) Irbesartan (N = 2067)
Hazard Ratio
(95% CI) P Value
No. of Patients 
with Event 
Event Rate per 
1000 Patient-Yr
No. of Patients 
with Event
Event Rate per 
1000 Patient-Yr
Death from any cause 436 52.3 445 52.6 1.00 (0.88–1.14) 0.98
Death from heart failure or hospitaliza-
tion for heart failure†
438 57.4 428 54.8 0.96 (0.84–1.09) 0.51
Death from a cardiovascular cause or 
nonfatal myocardial infarction  
or stroke
400 49.4 402 48.9 0.99 (0.86–1.13) 0.84
Death from a cardiovascular cause 302 36.3 311 36.7 1.01 (0.86–1.18) 0.92
Hospitalization for a protocol-specified 
cardiovascular cause
537 74.3 521 70.6 0.95 (0.85–1.08) 0.44
Hospitalization for worsening heart  
failure
336 44.0 325 41.6 0.95 (0.81–1.10) 0.50
Hospitalization for any cause 1126 199.8 1152 203.6 1.02 (0.94–1.11) 0.64
Change in score on the Minnesota Living 
with Heart Failure scale at 6 mo‡
0.85
Median −7 −8
Interquartile range −19 to 0 −19 to 1
Change in NT pro-BNP at 6 mo (pg/ml) 0.14
Median −2 −13 
Interquartile range −125 to 119 −149 to 100
* Event rates were normalized for the duration of follow-up before the event occurrence.
† Death from heart failure includes death due to pump failure and sudden death. NT pro-BNP denotes plasma N-terminal pro B–type natri-
uretic peptide.
‡ Possible scores range from 0 to 105, with lower scores indicating a better quality of life.
Table 4. Drug Discontinuations and Adverse Events.
Variable
Placebo
(N = 2061)
Irbesartan
(N = 2067) P Value
no. (%)
Discontinuation of  the study drug*
Any reason 684 (33) 702 (34) 0.60
Adverse event 288 (14) 331 (16) 0.07
Patient’s choice 223 (11) 208 (10) 0.43
Serious adverse event
Hypotension 62 (3) 60 (3) 0.84
Renal failure 57 (3) 69 (3) 0.29
Hyperkalemia 9 (<1) 12 (<1) 0.34
* Reasons for discontinuation did not include death.
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from any cause and hospitalization for cardio-
vascular causes.
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